Publication Date:
2024-03-30
Description:
The Neuroproteomics Special Issue overviews the unique challenges that must be addressed to carry out meaningful MS/proteomics analyses on neural tissues and the technologies that are available to meet these challenges. The articles on Alzheimer’s disease, addiction, and schizophrenia illustrate how MS/proteomics technologies can be used to improve our ability to diagnose and understand the molecular basis for neurological diseases. Several articles will be of interest to investigators beyond the field of neurological disorders. The review on the discovery of biofluid biomarkers of neurodegenerative dementias will be of interest to investigators searching for other disease biomarkers. Similarly, the review on the role of neuroproteomics in elucidating mechanisms of drug addiction provides an overview of the utility of MS/proteomics approaches for addressing critical questions in addiction neuroscience that should be applicable to investigators involved in virtually any area of biomedical research. Likewise, the article on developing targeted MS approaches for quantifying postsynaptic density proteins will be useful for any investigator who wishes to design targeted assays for virtually any protein. Finally, the peroxidase-mediated proximity labeling technology, described in the article on mapping the proteome of the synaptic cleft, will be of interest to investigators interested in mapping other spatially restricted proteomes.
Keywords:
R5-920
;
RC346-429
;
n/a
;
analgesia
;
quantitative phosphoproteomics
;
neurodegeneration
;
neuron
;
neuronal circuits
;
mating
;
sex-specific differences
;
AMPA receptor complex
;
parallel reaction monitoring
;
splicing
;
phosphorylation
;
peptidylglycine ?-amidating monooxygenase
;
pherophorin
;
Alzheimer’s disease
;
neuroscience
;
yohimbine
;
synapses
;
adolescence
;
conformational antibody
;
opioid receptors
;
protein interaction networks
;
Alzheimer’s Disease
;
transmembrane AMPA receptor regulatory protein
;
neuroproteome
;
ethanol
;
U1 snRNP
;
mass spectroscopy
;
morphine
;
protein phosphatase-1
;
neuroproteomics
;
axons
;
reinstatement
;
DIA
;
voltage gated channels
;
prohormone convertase
;
postsynaptic density
;
neuroimmune
;
dendrites
;
carboxypeptidase
;
GPCR signaling
;
CaMKII
;
FGF14
;
SynCAM
;
nicotinic receptor
;
synaptic plasticity
;
plasma
;
serum
;
corticosterone
;
dopamine
;
Receptor-type tyrosine-protein phosphatase zeta
;
Ptprz1
;
PRM
;
cell type
;
schizophrenia
;
laser capture microdissection
;
synapse specificity
;
LC-MS/MS
;
mouse
;
drug abuse
;
synaptic cleft
;
striatum
;
Cadm
;
cytokine
;
spinophilin
;
PSD
;
trans-synaptic adhesion
;
nicotine
;
proximity labeling
;
biomarkers
;
addiction
;
PKA
;
synapse
;
proteome
;
signal peptide
;
ventral tegmental area
;
protein aggregation
;
cerebrospinal fluid
;
bioinformatics
;
progressive ratio
;
interactome
;
subtilisin
;
affinity chromatography
;
basal ganglia
;
cocaine
;
targeted proteomics
;
postsynaptic
;
mass spectrometry
;
connectome
;
quantitative mass spectrometry
;
biotinylation
;
proteomics
;
amphetamine
;
autism
;
data-independent acquisition
;
excitatory/inhibitory tone
;
neuropeptidomics
;
matrix metalloproteinase
;
cilia
;
R-PTP-zeta
;
cognitive impairment
Language:
English
Format:
application/octet-stream
Permalink
